BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 2005;5:226-243. [PMID: 16041392 DOI: 10.1038/sj.tpj.6500320] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Li L, Schaid DJ, Fridley BL, Kalari KR, Jenkins GD, Abo RP, Batzler A, Moon I, Pelleymounter L, Eckloff BW, Wieben ED, Sun Z, Yang P, Wang L. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet Genomics 2012;22:105-16. [PMID: 22173087 DOI: 10.1097/FPC.0b013e32834dd7e2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
2 Danesi R, Altavilla G, Giovannetti E, Rosell R. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics 2009;10:69-80. [PMID: 19102717 DOI: 10.2217/14622416.10.1.69] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
3 Nakahara O, Takamori H, Tanaka H, Sakamoto Y, Ikuta Y, Furuhashi S, Watanabe M, Beppu T, Hirota M, Kanemitsu K, Baba H. Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer. Int J Clin Oncol 2010;15:39-45. [DOI: 10.1007/s10147-009-0008-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
4 Hashimoto A, Hashimoto S, Sugino H, Yoshikawa A, Onodera Y, Handa H, Oikawa T, Sabe H. ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance. Oncogenesis 2016;5:e259. [PMID: 27617643 DOI: 10.1038/oncsis.2016.60] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
5 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
6 Owen A, Khoo SH. Pharmacogenetics of antiretroviral agents. Curr Opin HIV AIDS 2008;3:288-95. [PMID: 19372981 DOI: 10.1097/COH.0b013e3282f7cda4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Meng X, Wang G, Guan R, Jia X, Gao W, Wu J, Yu J, Liu P, Yu Y, Sun W, Dong H, Fu S. Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells. Pharmacogenomics 2015;16:23-34. [DOI: 10.2217/pgs.14.159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Takeda M, Okamoto I, Hirabayashi N, Kitano M, Nakagawa K. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2011;73:103-9. [DOI: 10.1016/j.lungcan.2010.10.022] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
9 Robinson WJ, Taylor AE, Lauga-Cami S, Weaver GW, Arroo RRJ, Kaiser M, Gul S, Kuzikov M, Ellinger B, Singh K, Schirmeister T, Botana A, Eurtivong C, Bhambra AS. The discovery of novel antitrypanosomal 4-phenyl-6-(pyridin-3-yl)pyrimidines. Eur J Med Chem 2021;209:112871. [PMID: 33070078 DOI: 10.1016/j.ejmech.2020.112871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Serdjebi C, Gattacceca F, Seitz JF, Fein F, Gagnière J, François E, Abakar-Mahamat A, Deplanque G, Rachid M, Lacarelle B, Ciccolini J, Dahan L. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. Ther Drug Monit 2017;39:290-6. [PMID: 28346313 DOI: 10.1097/FTD.0000000000000399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Kim S, Park DH, Kim TH, Hwang M, Shim J. Functional analysis of pyrimidine biosynthesis enzymes using the anticancer drug 5-fluorouracil in Caenorhabditis elegans. FEBS J 2009;276:4715-26. [PMID: 19645718 DOI: 10.1111/j.1742-4658.2009.07168.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
12 Puglisi F, Andreetta C, Valent F, Minisini AM, Rijavec E, Russo S, Mansutti M, Cardellino G, Pizzolitto S, Di Loreto C. Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. Anti-Cancer Drugs 2007;18:883-8. [DOI: 10.1097/cad.0b013e32816ebede] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
13 Soriano V, Vispo E, de Mendoza C, Labarga P, Fernandez-montero JV, Poveda E, Treviño A, Barreiro P. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opinion on Pharmacotherapy 2013;14:1161-70. [DOI: 10.1517/14656566.2013.795543] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
14 Kocabas NA, Aksoy P, Pelleymounter LL, Moon I, Ryu JS, Gilbert JA, Salavaggione OE, Eckloff BW, Wieben ED, Yee V, Weinshilboum RM, Ames MM. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos 2008;36:1951-9. [PMID: 18556440 DOI: 10.1124/dmd.108.020925] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
15 Owen A. The impact of host pharmacogenetics on antiretroviral drug disposition. Curr Infect Dis Rep 2006;8:401-8. [PMID: 16934200 DOI: 10.1007/s11908-006-0052-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
16 Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S, Harada T, Harada M, Takamura K, Oizumi S, Kinoshita I, Katsuura Y, Honjo O, Kojima T, Dosaka-akita H, Isobe H, Munakata M, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. Cancer Chemother Pharmacol 2014;74:1149-57. [DOI: 10.1007/s00280-014-2589-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
17 Tominaga T, Tsuchiya T, Mochinaga K, Arai J, Yamasaki N, Matsumoto K, Miyazaki T, Nagasaki T, Nanashima A, Tsukamoto K, Nagayasu T. Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer. BMC Cancer 2016;16:354. [PMID: 27268079 DOI: 10.1186/s12885-016-2392-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
18 Hashimoto A, Oikawa T, Hashimoto S, Sugino H, Yoshikawa A, Otsuka Y, Handa H, Onodera Y, Nam JM, Oneyama C, Okada M, Fukuda M, Sabe H. P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. J Cell Biol 2016;213:81-95. [PMID: 27044891 DOI: 10.1083/jcb.201510002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
19 Yin J, Li X, Zhou H, Liu Z. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine. Pharmacogenomics 2016;17:1365-78. [DOI: 10.2217/pgs-2016-0074] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
20 Xu J, Wang L, Li J. Biological network module-based model for the analysis of differential expression in shotgun proteomics. J Proteome Res 2014;13:5743-50. [PMID: 25327611 DOI: 10.1021/pr5007203] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
21 Soo RA, Wang LZ, Ng SS, Chong PY, Yong WP, Lee SC, Liu JJ, Choo TB, Tham LS, Lee HS, Goh BC, Soong R. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009;63:121-7. [PMID: 18538445 DOI: 10.1016/j.lungcan.2008.04.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
22 Hartford CM, Dolan ME. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics 2007;8:1159-68. [PMID: 17924831 DOI: 10.2217/14622416.8.9.1159] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
23 Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen T, Houlston RS. Prognostic significance of folate metabolism polymorphisms for lung cancer. Br J Cancer 2007;97:247-52. [PMID: 17533396 DOI: 10.1038/sj.bjc.6603830] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ichikawa W, Sasaki Y. Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients. Int J Clin Oncol 2008;13:206-11. [DOI: 10.1007/s10147-008-0786-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
25 Kim YI. Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol 2009;5:523-42. [PMID: 19450180 DOI: 10.2217/fon.09.26] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
26 Ichikawa W. Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer. 2006;9:145-155. [PMID: 16952032 DOI: 10.1007/s10120-006-0373-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
27 Aksoy P, Zhu MJ, Kalari KR, Moon I, Pelleymounter LL, Eckloff BW, Wieben ED, Yee VC, Weinshilboum RM, Wang L. Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics. Pharmacogenet Genomics 2009;19:567-76. [PMID: 19623099 DOI: 10.1097/FPC.0b013e32832c14b8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
28 Glaysher S, Yiannakis D, Gabriel FG, Johnson P, Polak ME, Knight LA, Goldthorpe Z, Peregrin K, Gyi M, Modi P, Rahamim J, Smith ME, Amer K, Addis B, Poole M, Narayanan A, Gulliford TJ, Andreotti PE, Cree IA. Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC Cancer 2009;9:300. [PMID: 19712441 DOI: 10.1186/1471-2407-9-300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
29 Huang X, Chen L, Li Z, Zheng B, Liu N, Fang Q, Jiang J, Rao T, Ouyang D. The efficacy and toxicity of antineoplastic antimetabolites: Role of gut microbiota. Toxicology 2021;460:152858. [PMID: 34273448 DOI: 10.1016/j.tox.2021.152858] [Reference Citation Analysis]
30 Bai JPF, Pacanowski M, Rahman A, Lesko LL. The Impact of Pharmacogenetics on the Clinical Outcomes of Prodrugs. In: Rautio J, editor. Prodrugs and Targeted Delivery. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2010. pp. 453-81. [DOI: 10.1002/9783527633166.ch16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Pilgrim CH, Brettingham-Moore K, Pham A, Murray W, Link E, Smith M, Usatoff V, Evans PM, Banting S, Thomson BN, Michael M, Phillips WA. mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury. HPB (Oxford) 2011;13:811-6. [PMID: 21999595 DOI: 10.1111/j.1477-2574.2011.00365.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
32 Takemoto S, Akagi K, Ono S, Tomono H, Honda N, Suyama T, Umeyama Y, Dotsu Y, Taniguchi H, Ogawara D, Senju H, Gyotoku H, Sugasaki N, Yamaguchi H, Nakatomi K, Fukuda M, Mukae H. Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis. Thorac Cancer 2021;12:2300-6. [PMID: 34255933 DOI: 10.1111/1759-7714.14055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Phan VH, Moore MM, Mclachlan AJ, Piquette-miller M, Xu H, Clarke SJ. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opinion on Drug Metabolism & Toxicology 2009;5:243-57. [DOI: 10.1517/17425250902800153] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 6.2] [Reference Citation Analysis]
34 Riggins RB, Mazzotta MM, Maniya OZ, Clarke R. Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Endocr Relat Cancer 2010;17:R213-31. [PMID: 20576803 DOI: 10.1677/ERC-10-0058] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
35 Cao D, Ziemba A, McCabe J, Yan R, Wan L, Kim B, Gach M, Flynn S, Pizzorno G. Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity. Mol Cancer Ther 2011;10:2330-9. [PMID: 21954436 DOI: 10.1158/1535-7163.MCT-11-0202] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
36 Phan VH, Tan C, Rittau A, Xu H, McLachlan AJ, Clarke SJ. An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opin Drug Metab Toxicol. 2011;7:1395-1410. [PMID: 21950349 DOI: 10.1517/17425255.2011.624513] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
37 Wan QL, Meng X, Fu X, Chen B, Yang J, Yang H, Zhou Q. Intermediate metabolites of the pyrimidine metabolism pathway extend the lifespan of C. elegans through regulating reproductive signals. Aging (Albany NY) 2019;11:3993-4010. [PMID: 31232697 DOI: 10.18632/aging.102033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
38 Xu X, Chen J. One-carbon metabolism and breast cancer: an epidemiological perspective. J Genet Genomics 2009;36:203-14. [PMID: 19376481 DOI: 10.1016/S1673-8527(08)60108-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
39 Adler S, Lindqvist J, Uddenberg K, Hyllner J, Strehl R. Testing potential developmental toxicants with a cytotoxicity assay based on human embryonic stem cells. Altern Lab Anim 2008;36:129-40. [PMID: 18522481 DOI: 10.1177/026119290803600204] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
40 Tripathy D. Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials. The Oncologist 2007;12:375-89. [DOI: 10.1634/theoncologist.12-4-375] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
41 Ravizza R, Molteni R, Gariboldi MB, Marras E, Perletti G, Monti E. Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. Eur J Cancer. 2009;45:890-898. [PMID: 19171477 DOI: 10.1016/j.ejca.2008.12.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
42 Lagisetty P, Vilekar P, Awasthi V. Synthesis of radiolabeled cytarabine conjugates. Bioorganic & Medicinal Chemistry Letters 2009;19:4764-7. [DOI: 10.1016/j.bmcl.2009.06.056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
43 Crews KR. Individualizing chemotherapeutic treatment of colorectal cancer. American Journal of Health-System Pharmacy 2006;63:S12-7. [DOI: 10.2146/ajhp060113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
44 Szöke D, Györffy A, Surowiak P, Tulassay Z, Dietel M, Györffy B. Identification of consensus genes and key regulatory elements in 5-fluorouracil resistance in gastric and colon cancer. Onkologie 2007;30:421-6. [PMID: 17848813 DOI: 10.1159/000104490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
45 Hamaguchi J, Nakagawa H, Takahashi M, Kudo T, Kamiyama N, Sun B, Oshima T, Sato Y, Deguchi K, Todo S, Nishimura S. Swainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines. Mol Cancer 2007;6:58. [PMID: 17883871 DOI: 10.1186/1476-4598-6-58] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
46 Lincz LF, Scorgie FE, Garg MB, Ackland SP. Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele. Int J Cancer. 2007;120:1930-1934. [PMID: 738222 DOI: 10.1002/ijc.22568] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 0.8] [Reference Citation Analysis]
47 Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 2009;10:1657-74. [PMID: 19842938 DOI: 10.2217/pgs.09.118] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 7.1] [Reference Citation Analysis]
48 Owen A, Pirmohamed M, Khoo SH, Back DJ. Pharmacogenetics of HIV therapy. Pharmacogenetics and Genomics 2006;16:693-703. [DOI: 10.1097/01.fpc.0000236338.41799.57] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
49 Shai RM, Reichardt JK, Chen TC. Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. Future Oncol 2008;4:525-34. [PMID: 18684063 DOI: 10.2217/14796694.4.4.525] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
50 Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet 2006;45:567-92. [PMID: 16719540 DOI: 10.2165/00003088-200645060-00002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
51 Kai K, Kitajima Y, Hiraki M, Satoh S, Tanaka M, Nakafusa Y, Tokunaga O, Miyazaki K. Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens. Cancer Lett 2007;258:45-54. [PMID: 17892912 DOI: 10.1016/j.canlet.2007.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
52 Soong R, Diasio RB. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics. 2005;6:835-847. [PMID: 16296946 DOI: 10.2217/14622416.6.8.835] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
53 Matsusaka S, Lenz HJ. Pharmacogenomics of fluorouracil -based chemotherapy toxicity. Expert Opin Drug Metab Toxicol 2015;11:811-21. [PMID: 25800061 DOI: 10.1517/17425255.2015.1027684] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
54 Zhu N, Gong Y, He J, Xia J, Chen X. Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis. Yonsei Med J 2013;54:1384-93. [PMID: 24142642 DOI: 10.3349/ymj.2013.54.6.1384] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
55 Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, Sasaki Y, Hirayama R. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer. 2006;119:1927-1933. [PMID: 16736497 DOI: 10.1002/ijc.22080] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
56 Abraham A, Varatharajan S, Abbas S, Zhang W, Shaji RV, Ahmed R, Abraham A, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 2012;13:269-82. [DOI: 10.2217/pgs.11.149] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
57 Veltkamp SA, Beijnen JH, Schellens JH. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist. 2008;13:261-276. [PMID: 18378536 DOI: 10.1634/theoncologist.2007-0215] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
58 Michalski CW, Erkan M, Sauliunaite D, Giese T, Stratmann R, Sartori C, Giese NA, Friess H, Kleeff J. Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer 2008;99:760-7. [PMID: 18728667 DOI: 10.1038/sj.bjc.6604528] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
59 Miwa T, Kanda M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Nakayama G, Koike M, Kodera Y. Albumin-Bilirubin Score Predicts Tolerability to Adjuvant S-1 Monotherapy after Curative Gastrectomy. J Gastric Cancer 2019;19:183-92. [PMID: 31245163 DOI: 10.5230/jgc.2019.19.e15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences 2011;18:700-11. [DOI: 10.1007/s00534-011-0376-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]